WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will present at the following investor conferences:
Guggenheim 5th Annual Inflammation, Neurology & Immunology (INI) Conference
Fireside Chat Date: Tuesday, November 7, 2023
Fireside Chat Time: 3:50 PM ET
Location: New York, NY
Evercore ISI 6th Annual HealthCONx Conference
Fireside Chat Date: Thursday, November 30, 2023
Fireside Chat Time: 10:50 AM ET
Location: Miami, FL
Live webcasts of the fireside chats will be available in the investor section of the company's website at investors.invivyd.com and will be archived for approximately 30 days following the events.
About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. Invivyd’s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with the potential to resist viral escape. The company is generating a robust pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications. Visit https://invivyd.com/ to learn more.
Contacts:
Scott Young
(781) 208-1747
This email address is being protected from spambots. You need JavaScript enabled to view it.
Gabriella Linville-Engler
(781) 208-0160
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.43 |
| Daily Change: | -0.01 -3.28 |
| Daily Volume: | 1,643,613 |
| Market Cap: | US$51.440M |
November 14, 2024 October 29, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
